Subduction Initiation Recorded in the Dadeville Complex of Alabama and Georgia, Southeastern United States

The Dadeville Complex of Alabama and Georgia (southeastern United States) represents the largest suite of exposed mafic-ultramafic rocks in the southern Appalachians. Due to poor preservation, chemical alteration, and tectonic reworking, a specific tectonic origin for the Dadeville Complex has been difficult to deduce. We obtained new whole-rock and mineral geochemistry coupled with zircon U-Pb geochronology to investigate the magmatic and metamorphic processes recorded by the Dadeville Complex, as well as the timing of these processes. Our data reveal an up-stratigraphic evolution in the geochemistry of the volcanic rocks, from forearc basalts to boninites. Our new U-Pb zircon crystallization data—obtained from three amphibolite samples—place the timing of forearc/protoarc volcanism no later than ca. 467 Ma. New thermobarometry suggests that the Dadeville Complex rocks subsequently experienced deep, high-grade metamorphism, at pressure-temperature conditions of \u3e7 kbar and \u3e760 °C. The data presented here support a model for formation of the Dadeville Complex in the forearc region of a subduction zone during subduction initiation and protoarc development, followed by deep burial/underthrusting of the complex during orogenesis

The origin(s) and geodynamic significance of Archaean ultramafic-mafic bodies in the mainland Lewisian Gneiss Complex, North Atlantic Craton

The geodynamic regime(s) that predominated during the Archaean remains controversial, with the plethora of competing models largely informed by felsic lithologies. Ultramafic-mafic rocks displaying distinctive geochemical signatures are formed in a range of Phanerozoic geotectonic environments. These rocks have high melting points, making them potentially useful tools for investigating Archaean geodynamic processes in highly metamorphosed regions. We present field mapping, petrography, traditional bulk-rock geochemistry, and platinum-group element geochemistry for 12 ultramafic-mafic bodies in the Lewisian Gneiss Complex (LGC), which is a highly metamorphosed fragment of the North Atlantic Craton in northwest Scotland. Our data indicate that most of these occurrences are layered intrusions emplaced into the tonalite-trondhjemite-granodiorite (TTG)-dominated crust prior to polyphase metamorphism, representing a significant re-evaluation of the LGC's magmatic evolution. Of the others, two remain ambiguous, but one (Loch an Daimh Mor) has some geochemical affinity with abyssal/orogenic peridotites and may represent a fragment of Archaean mantle, although further investigation is required. The ultramafic-mafic bodies in the LGC thus represent more than one type of event/process. Compared with the TTG host rocks, these lithologies may preserve evidence of protolith origin(s), with potential to illuminate tectonic setting(s) and geodynamic regimes of the early Earth

Re-evaluating ambiguous age relationships in Archean cratons: Implications for the origin of ultramafic-mafic complexes in the Lewisian Gneiss Complex

Archean ultramafic-mafic complexes have been the focus of important and often contentious geological and geodynamic interpretations. However, their age relative to the other components of Archean cratons are often poorly-constrained, introducing significant ambiguity when interpreting their origin and geodynamic significance. The Lewisian Gneiss Complex (LGC) of the northwest Scottish mainland – a high-grade, tonalite-trondhjemite-granodiorite (TTG) terrane that forms part of the North Atlantic Craton (NAC) – contains a number of ultramafic-mafic complexes whose origin and geodynamic significance have remained enigmatic since they were first described. Previous studies have interpreted these complexes as representing a wide-range of geological environments, from oceanic crust, to the sagducted remnants of Archean greenstone belts. These interpretations, which are often critically dependent upon the ages of the complexes relative to the surrounding rocks, have disparate implications for Archean geodynamic regimes (in the NAC and globally). Most previous authors have inferred that the ultramafic-mafic complexes of the LGC pre-date the TTG magmas. This fundamental age relationship is re-evaluated in this investigation through re-mapping of the Geodh’ nan Sgadan Complex (where tonalitic gneiss reportedly cross-cuts mafic rocks) and new mapping of the 7 km2 Ben Strome Complex (the largest ultramafic-mafic complex in the LGC), alongside detailed petrography and spinel mineral chemistry. This new study reveals that, despite their close proximity in the LGC (12 km), the Ben Strome and Geodh’ nan Sgadan Complexes are petrogenetically unrelated, indicating that the LGC (and thus NAC) records multiple temporally and/or petrogenetically distinct phases of ultramafic-mafic Archean magmatism that has been masked by subsequent high-grade metamorphism. Moreover, field observations and spinel mineral chemistry demonstrate that the Ben Strome Complex represents a layered intrusion that was emplaced into a TTG-dominated crust. Further to representing a significant re-evaluation of the LGC’s magmatic evolution, these findings have important implications for the methodologies utilised in deciphering the origin of Archean ultramafic-mafic complexes globally, where material suitable for dating is often unavailable and field relationships are commonly ambiguous

Origin of ultramafic–mafic bodies on the Isles of Lewis and Harris (Scotland, UK): Constraints on the Archean–Paleoproterozoic evolution of the Lewisian Gneiss Complex, North Atlantic Craton

The Lewisian Gneiss Complex (LGC) is a tonalite-trondhjemite-granodiorite (TTG)-dominated fragment of the North Atlantic Craton (NAC) in northwest Scotland. End-member models describe the LGC as representing either a continuous piece of Archean crust or up to 12 geologically distinct Archean terranes, with interpretations sitting on a spectrum between these end-members. There is particular uncertainty over the correlations between the Archean–Paleoproterozoic magmatic and metamorphic events recorded by mainland part of the LGC and the part exposed on the Outer Hebridean islands of Lewis and Harris. In this paper, we present the results of field mapping, petrography, and major, trace and platinum-group element (PGE) bulk-rock geochemistry for four ultramafic–mafic bodies in Lewis and Harris, namely: Maaruig, Loch Mhorsgail, Coltraiseal Mor and Beinn a’ Chuailean. We consider the effects of metamorphism and element mobility, their petrogenesis, and potential correlations with ultramafic–mafic rocks elsewhere in the LGC. Our data indicate that the studied ultramafic–mafic rocks can be subdivided into two petrologically distinct groups. Metaperidotites and metapyroxenites from Maaruig and Loch Mhorsgail are interpreted as Archean (>2.8 Ga) cumulates distinct from anything currently identified in the mainland LGC, with this interpretation based on distinctive modal layering, a discordance with surrounding TTG gneiss, fractionated PGE patterns ([Pd/Ir]N = 1.3–6.6) and negative HFSE anomalies ([Nb/La]N = 0.2–0.8). Metagabbronorites from Coltraiseal Mor and Beinn a’ Chuailean, which also exhibit negative high field strength-element (HFSE) anomalies ([Nb/La]N = 0.2–0.7) and show mildly fractionated ([Pd/Ir]N = 1.2–2.8) PGE patterns, most likely represent deformed Paleoproterozoic dykes. These occurrences could be correlatives of a suite of ca. 2.4 Ga mafic dykes exposed throughout the mainland LGC (the Scourie Dykes), with the Outer Hebridean occurrences having experienced more intense Paleoproterozoic (Laxfordian) deformation/reworking. These interpretations suggest that the LGC lithologies of Lewis and Harris were proximal to the mainland LGC’s Central Region by the early Paleoproterozoic but raises the possibility that they were distinct crustal blocks in the Mesoarchean

Argon Laser Photocoagulation For Macular Edema In Branch Vein Occlusion

The Branch Vein Occlusion Study is a multi-center, randomized, controlled clinical trial designed to answer several questions regarding the management of complications of branch vein occlusion. This report discusses the question, “Is argon laser photocoagulation useful in improving visual acuity in eyes with branch vein occlusion and macular edema reducing vision to 20/40 or worse?” One hundred thirty-nine eligible eyes were assigned randomly to either a treated or an untreated control group. Comparing treated patients to control patients (mean follow-up 3.1 years for all study eyes), the gain of at least two lines of visual acuity from baseline maintained for two consecutive visits was significantly greater in treated eyes (P = .00049, logrank test). Because of this improvement in visual acuity with argon laser photocoagulation of macular edema from branch vein occlusion, we recommend laser photocoagulation for patients with macular edema associated with branch vein occlusion who meet the eligibility criteria of this study

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

BACKGROUN

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients